Cardionovum LEGFLOW®, the 3rd generation Drug-Coated Balloon. Prof Marone form Pavia University, Italy, demonstrates his preferred method for DCB treatment in a 69-year old woman. A short occlusion in a 150mm long lesion of left SFA is treated without predilatation with a LEGFLOW® 0.018”.
LEGFLOW® DCB is a safe, easily handled, low-stress device. Thanks to the stable SAFEPAX® coating matrix, based on lipophilic ammonium salt, it can be easily handled without the risk of the drug leaking onto operators’ gloves. The stability of SAFEPAX® also allows crossing of hemostatic valves without the need for a dedicated introducer to prevent coating debris.
The elastic coating ensures smooth and easy crossing of complex anatomies and the optimised PTA hypotube shaft secure kink resistance and pushability.
Prof Marone: “I find that the stability of the SAFEPAX® coating generates a relaxed working environment with LEGFLOW®. We dont need to rush to reach the lesion since paclitaxel leakage is minimised.”
Like some operators, Prof Marone has chosen to do without predilatation, in order to minimize dissection issues, procedure time and procedure cost. This is off-label for the device and is not recommended by the manufacturer.
Prof Marone: “Personally I prefer to do away with predilatation and I have found it works well. I call this Streamlined DCB.”
The lipophilicity of the SAFEPAX® coating guarantees an effective transfer of paclitaxel from the balloon to the vessel wall to effect a positive remodelling of the treated segment.
These developments make LEGFLOW®, the 3rd generation DCB, a valuable treatment option for SFA, popliteal and BTK arteries.
Cardionovum LEGFLOW® is available in a wide size range with 0.035"; 0.018"; 0.014" OTW and 0.014" RX platforms